Arch Therapeutics, Inc. Disclosure


Arch Therapeutics, Inc. (OTCQB: ARTH) is a client of PCG Advisory, Inc. ARTH has an agreement in place to pay PCG a monthly cash fee of $4,000, plus a one-time option granted to PCG to purchase 300,000 shares of common stock, restricted under Rule 144, for PCG investor awareness and investor relations advisory services.

Investor awareness and investor relations services and programs are designed to help small-cap companies communicate their investment characteristics. PCG investor awareness and advisory services include multimedia marketing and other awareness services.